Cosciens, a biotechnology firm, recently experienced a 32% stock price decline after its growth hormone test failed to meet the primary endpoint in a Phase III clinical trial. The study intended to assess the test’s efficacy but did not deliver the anticipated results, marking a significant setback for the company’s development efforts. This failure raises concerns about the viability of Cosciens’ growth hormone product in the market and could have serious financial repercussions. Investors are closely watching the situation, as the company’s stock has been unstable, and this news may further impact its future plans and performance.